RiaSTAP
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- RiaSTAP
- Generic name
- FIBRINOGEN HUMAN
- Manufacturer
- CSL Behring GmbH
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 903dc8d0-39da-462c-9dac-004e0c7a26cc
- SPL ID
- 703efe5b-eb9f-4690-abb8-e446feaa702f
- Version
- 19
- Effective date
- 2025-12-29
- Source export date
- 2026-11-13
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:35:17
| Harmonized routes |
|---|
| INTRAVENOUS, SUBCUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125317 | derived:openfda.application_number |
| application number | BLA125317 | openfda.application_number | |
| brand name | RiaSTAP | openfda.brand_name | |
| generic name | FIBRINOGEN HUMAN | openfda.generic_name | |
| manufacturer name | CSL Behring GmbH | openfda.manufacturer_name | |
| ndc | package | 63833-891-51 | openfda.package_ndc |
| ndc | package | 63833-891-90 | openfda.package_ndc |
| ndc | package | 63833-892-90 | openfda.package_ndc |
| ndc | package | 63833-892-51 | openfda.package_ndc |
| ndc | product | 63833-891 | openfda.product_ndc |
| ndc | product | 63833-892 | openfda.product_ndc |
| ndc11 | package | 63833089290 | derived:openfda.package_ndc |
| ndc11 | package | 63833089151 | derived:openfda.package_ndc |
| ndc11 | package | 63833089251 | derived:openfda.package_ndc |
| ndc11 | package | 63833089190 | derived:openfda.package_ndc |
| rxcui | 831506 | openfda.rxcui | |
| rxcui | 831509 | openfda.rxcui | |
| spl id | 703efe5b-eb9f-4690-abb8-e446feaa702f | id | |
| spl set id | 903dc8d0-39da-462c-9dac-004e0c7a26cc | set_id | |
| unii | N94833051K | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment. ( 5.1 ) Thrombotic events have been reported in patients receiving RIASTAP. Weigh the benefits of administration versus the risks of thrombosis. ( 5.2 ) Because RIASTAP is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.3 ) 5.1 Hypersensitivity Reactions Allergic reactions may occur. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension) occur, immediately discontinue administration [see Patient Counseling Information (17) ] . The treatment required depends on the nature and severity of the reaction. 5.2 Thrombosis Thrombosis may occur spontaneously in patients with congenital fibrinogen deficiency with or without the use of fibrinogen replacement therapy. 1 Thromboembolic events have been reported in patients treated with RIASTAP. Weigh the benefits of RIASTAP administration versus the risk of thrombosis. Monitor patients receiving RIASTAP for signs and symptoms of thrombosis [see Patient Counseling Information (17) ]. 5.3 Transmissible Infectious Agents Because RIASTAP is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by a process demonstrated to inactivate and/or remove certain viruses during manufacturing [see Description (11) ] . Despite these measures, such products may still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products [see Patient Counseling Information (17) ] . All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to CSL Behring Pharmacovigilance at 1-866-915-6958.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most serious adverse reactions reported in clinical studies or through postmarketing surveillance following RIASTAP treatment are thromboembolic episodes, including myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis, and allergic-anaphylactic reactions. The most common adverse reactions observed in more than one subject in clinical trials (frequency >1%) were fever and headache. The most serious adverse reactions observed are thrombotic episodes (pulmonary embolism, myocardial infarction, deep vein thrombosis) and anaphylactic reactions. ( 6 ) The most common adverse reactions observed in clinical studies (frequency >1%) were fever and headache. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice. The safety and efficacy of fibrinogen concentrate (human) for routine prophylaxis, treatment of bleeding or surgery in subjects with congenital fibrinogen deficiency was evaluated in a retrospective, multicenter trial with a prospective one-year follow-up period. Twenty-two subjects between 2 to 78 years with a mean age of 34 years were enrolled, with treatment recorded during the retrospective period from an age of less than 1 year. Thirteen of the 22 (59.1%) subjects were female, 21 (95.5%) subjects were white, and 1 (4.5%) subject Asian [see Clinical Studies (14) ] . The adverse reactions reported in the retrospective period were visual impairment, chest discomfort, chest pain, cough, wheezing, flushing, and venous thrombosis of the limb [1 event each] and dyspnea [2 events]. No adverse reactions were found in the prospective period. 6.2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. The following adverse reactions, identified by system organ class, have shown a possible causal relationship with RIASTAP. Allergic-anaphylactic reactions: anaphylaxis , dyspnea, rash Cardiovascular: thromboembolic complications such as myocardial infarction, pulmonary embolism, and deep vein thrombosis [see Warnings and Precautions (5.2) ] General/Body as a Whole: chills, nausea, vomiting
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.